Single Dose of the Psychedelic Mebufotenin by Nose for Hard-to-Treat Depression: A Randomized Clinical Trial

Intranasal mebufotenin may offer a more accessible treatment option for treatment-resistant depression.

• Psychedelics have shown promise for treatment-resistant depression but require extended in-clinic monitoring.
• Intranasal mebufotenin is a compound that could potentially reduce logistical barriers associated with traditional psychedelics.
• It acts on specific serotonin receptors, which are linked to mood regulation.
• The use of mebufotenin is associated with shorter psychedelic experiences compared to other compounds.

Simplified